Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

Dario Ribero, Huamin Wang, Matteo Donadon, Daria Zorzi, Melanie B. Thomas, Cathy Eng, David Z. Chang, Steven A. Curley, Eddie K. Abdalla, Lee M. Ellis, Jean Nicolas Vauthey

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. METHODS. A total of 105 consecutive patients treated preoperatively with 5FU/OX chemotherapy with (n = 62) or without (n = 43) bevacizumab were analyzed. The response to chemotherapy was evaluated by pathologic analysis of tumor viability (percentage of viable tumor in relation to tumor surface area). The incidence and grade of hepatic sinusoidal dilation were also investigated. RESULTS. Bevacizumab-containing regimens significantly reduced the degree of tumor viability compared with 5FU/OX-only chemotherapy (32.9% vs 45.3%; P = .02). After stratification according to the magnitude of tumor viability, a higher proportion of patients treated with bevacizumab than without had

Original languageEnglish
Pages (from-to)2761-2767
Number of pages7
JournalCancer
Volume110
Issue number12
DOIs
Publication statusPublished - Dec 15 2007

Keywords

  • Bevacizumab
  • Colorectal liver metastases
  • Hepatotoxicity
  • Oxaliplatin
  • Sinusoidal dilatation
  • Tumor response

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases'. Together they form a unique fingerprint.

Cite this